Notably, PRMT2 displayed contradictory expression patterns, with a marginal decline observed in stage III/V compared to that in stage II, whereas elevated PRMT2 expression was negatively correlated with the overall survival outcomes of HCC patients. Here, PRMT2 is linked to hepatocellular carcinoma.